Professional Documents
Culture Documents
Bioaviabality Bioequivalence 2nd Sem M.pharm PDF
Bioaviabality Bioequivalence 2nd Sem M.pharm PDF
Bioavailability:
It is rate and extent of absorption of unchanged drug from its dosage form.
For examples: Rate (time or rapidity) - acute conditions- asthma, pain etc.
Extent (amount) – chronic conditions- hypertension.
If the size of the dose to be administered is same, then bioavailability of a drug from its dosage form depends
upon 3 major factors –
1} Pharmaceutical factors
2} Patent related factors
3} Route of administration
Influence of route of administration
PARENTRAL> ORAL> RECTAL>TOPICAL ------- with few exceptions
Systemic availability: - The amount of drug that reaches the systemic circulation is called as Systemic availability
or simply Availability. It is denoted by F.
F = Bioavailable dose / Administered dose
This method is based on the principle that the urinary excretion of unchanged drug is directly proportional to
the plasma concentration of drug.
It can be performed if
-At least 20% of administered dose is excreted unchanged in urine.
The study is useful for
Drugs that extensively excreted unchanged in urine eg. Thiazide diuretics.
Drugs that have urine as site of action eg. Urinary antiseptics like nitrofurontoin.
Steps involved:
Collection of urine at regular intervals for 7 half lifes.
Analysis of unchanged drug in collected sample.
Determination of amount of drug at each interval and cumulative as well.
Pharmacodynamics methods:
1. Acute pharmacological response:
When bioavailability measurement by pharmacokinetic methods is difficult, inaccurate or non-reproducible
this method is used. Such as ECG, EEG, Pupil diameter etc.
It can be determined by dose response graphs. Responses measure for at least 3 half lifes.
Disadvantages:
Pharmacological response is variable and accurate correlation drug and formulation is difficult.
Observed response may be due to active metabolite.
2. Therapeutic response:
This method is based on observing clinical response in patients.
Drawbacks:
Quantitation of observed response is too improper.
The physiological status of subject assumed that does not change significantly over duration of study.
If multiple dose protocols are not involved. Patient receive only single dose for few days or a week
The patient’s receiving more than one drug treatment may be compromised due to drug-drug
interaction.
It is defined as the predictive mathematical model that describes the relationship between in vitro property (rate &
extent of dissolution) and in vivo response (plasma drug concentration).
Objective:
The main objective of developing and evaluating IVIVC is to use dissolution test to serve as alternate for in vivo study
in human beings.
To ensure batch to batch consistency.
To serve as a tool for the development of new dosage form.
Approaches of IVIVC:
1. By establishing a relationship, usually linear, between the in vitro dissolution & the in vivo bioavailability
parameters.
2. By using the data from previous bioavailability studies to modify the dissolution methodology in order to
arrive meaningful IVIVC.
Correlations of IVIVC:
1. Correlations based on the plasma level data.
2. Correlations based on the urinary excretion data.
3. Correlations based on the pharmacologic response.
Levels IVIVC:
Level A: The highest category of correlation. A correlation of this type is generally linear and represents a point-to-
point relationship between in vitro dissolution and the in vivo input rate (e.g., the in vivo dissolution of the drug
from the dosage form)
Advantages: serves as alternate for in vivo study, change in manufacturing. Procedure or formula can be justified
without human studies.
Level B: The mean in vitro dissolution time is compare with mean in vivo residence time. It is not point to point
correlation. Data can be used for quality control standards. A Level B IVIVC uses the principles of statistical moment
analysis. The mean in vitro dissolution time is compared either to the mean residence time or to the mean in vivo
dissolution time. A Level B correlation does not uniquely reflect the actual in vivo plasma level curve, because a
number of different in vivo curves will produce similar mean residence time values.
Level C: It is single point correlation. e.g. t50%, Tmax, Cmax. This level is only useful as guide for formulation
development or quality control.
Level In vitro In vivo
A Dissolution curve Input (absorption) curves
B Statistical moments: MDT Statistical moments: MRT,
MAT, etc.
C Disintegration time,Time to have Cmax, Tmax, Ka, Time to have
10,50,90% dissolved, 10,50,90% absorbed,AUC
Dissolution rate, Dissolution efficiency (total or cumulative),
Table 1.Various parameters used in IVIVC depending on the level.
Bioequivalence of two products can be assessed using in vitro standards, pharmacokinetic profile, clinical or
pharmacodynamic end points. Different approaches for determination of bioequivalence of a drug product are:
An in vivo test in humans in which the concentration of the active ingredient and when appropriate, its
active metabolites, in blood, plasma, serum or other suitable biological fluid is measured as a function of
time.
An in vivo test in humans in which the urinary excretion of the active ingredient and when appropriate, its
active metabolites are measured as a function of time.
An in vitro test that has been correlated with and is predictive of human bioavailability profile or the one
acceptable to FDA (e.g. dissolution rate test) that ensures human in vivo bioavailability.
An in vivo test in humans in which an appropriate pharmacological effect of the active ingredient and when
appropriate, its active metabolites are measured as a function of time if this effect can be measured with
adequate accuracy, sensitivity and reproducibility.
Well-controlled clinical trials that establish the efficacy and safety of the drug product, for purpose of
determining bioavailability, or comparative clinical trials, for purpose of demonstrating bioequivalence.
Any other approach considered adequate by the FDA to measure bioavailability or ascertain bioequivalence
In vitro bioequivalence studies: If none of the above criteria is applicable comparative in vitro dissolution studies
can be done.
Biowaivers: In vivo studies can be exempted under certain conditions.
1. Drug product only differ in strength of drug provided,
Their pharmacokinetics are linear, Drug & excipient ratio is same,
Bboth products manufactured by same manuf. at same site.
Bioequivalence study done for original product, dissolution rate same under same conditions.
2. The method of production slightly modified in a way that not affect bioavailability.
3. The drug product meet following requirements: The product is in solubilised form, no excipients affecting
absorption, Topical use, Oral but not absorbed, inhalation as gas or vapour.
2. Confidence interval approach: It is also called as two one-sided procedure and used to demonstrate if
bioavailability of test product is too low or too high in comparison to reference product. 90% confidence interval of
two drug products must be within ±20% for bioavailability parameters such as AUC or Cmax. (i.e. between 80 to 102
%). For log transformed data 90% confidence interval is set at 80-125%.
Bioequivalence Studies:
Equivalence: - It is a relative term that compares drug product with respect to a specific characteristic or function or
to a defined set of standards.
1} Chemical equivalence: - When two or more drug products contain the same chemical substance as an active
ingredient in the same amount it is called chemical equivalence.
2} Pharmaceutical equivalence:- When two or more drug products are identical in strength, quality, purity, content
uniformity, disintegration, dissolution characteristics, they may however differ in containing different excipients,
called as pharmaceutical equivalence.
3} Bioequivalence:- It is relative term that denotes drug substance in two or more identical dosage forms, reaches the
systemic circulation at the same relative rate and to the same relative extent i.e. their plasma concentration-time
profiles will be identical without significant statistical differences.
When statistical differences are observed in the bioavailability of two or more drug products, Bioequivalence is
indicated.
4} Therapeutic Equivalence: - When two or more drug products that contain the same therapeutically active
ingredient, elicit identical pharmacologic effects and can control the disease to the same extent.
METHODS:
1. Micronization
2. Use of surfactant
3. Use of salt forms
4. Alteration of pH of the drug microenvironment
5. Use of metastable polymorphs
6. Solute – solvent complexation
7. Solvent deposition
8. Selective absorption on insoluble carrier
9. Solid solution
Use of solid solution
Use of eutectic mixture
Use of solid dispersion
10. Molecular encapsulation with cyclodextrins
11. Use of Co solvents.
12. Hydrotropy.
2. Use of surfactants.
‘Surfactants promote wetting & penetration of fluids into solid drug particles.’
Surfactants are amphiphilic in nature having a polar end (the circular head) and non-polar end (the tail). When a
surfactant such as tween-80, sodium lauryl sulphate is placed in water, it will form micelles. A non-polar drug will
partition into the hydrophobic core of the micelle and the polar tail will solubilize the complex. This has been
illustrated by solubilization and wetting effects of bile salts on the dissolution of steroids
E.g. Spironolactone
6. Solute-solvent complexation:
Solvates of drugs with organic solvents (pseudo polymorphs) have higher aqueous solubility than their respective
hydrates or original drug.
E.g. 1:2 Griseofulvin – Benzene solvate.
8. Eutectic mixture.
It is intimately blended physical mixture of two crystalline components.
Paracetamol –urea, Griseofulvin – urea & Griseofulvin-succinic acid
Disadvantage:
Not useful in:
Drugs which fail to crystallize from mixed melt.
Thermo labile drugs
Carrier like succinic acid decompose at their melting point.
11. Hydrotropy.
Hydrotropy is a solubilization process whereby addition of large amounts of a second solute (Hydrotropic agents)
results in an increase in the aqueous solubility of another solute. Solute consists of alkali metal salts of various
organic acids. Hydrotropic agents are ionic organic salts. Additives or salts that increase solubility in given solvent
are said to “salt in” the solute and those salts that decrease solubility “salt out” the solute. Several salts with large
anions or cations that are themselves very soluble in water results in “salting in” of non-electrolytes called
“hydrotropic salts” a phenomenon known as “Hydrotropism”. The solubility of rofecoxib was enhanced by using
hydrotropes such as urea and nicotinamide
THANK YOU